Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 9, 2009, Pages 3837-3846

  Tarning, Joel ^a,b   McGready, Rose ^a,b,c   Lindegardh, Niklas ^a,b   Ashley, Elizabeth A ^c   Pimanpanarak, Mupawjay ^c   Kamanikom, Benjamas ^a   Annerberg, Anna ^a   Day, Nicholas P J ^a,b   Stepniewska, Kasia ^a,b   Singhasivanon, Pratap ^a   White, Nicholas J ^a,b   Nosten, François ^a,b,c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c SHOKLO MALARIA RESEARCH UNIT   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; BENFLUMETOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; FEMALE; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECOND TRIMESTER PREGNANCY; SIMULATION; THIRD TRIMESTER PREGNANCY; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; ANIMALS; ANTIMALARIALS; ARTEMISININS; ETHANOLAMINES; FEMALE; FLUORENES; HUMANS; LOGISTIC MODELS; MALARIA, FALCIPARUM; PREGNANCY; YOUNG ADULT;

EID: 70349119891     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00195-09     Document Type: Article

References (59)

1. Abdelrahim, I. I., I. Adam, G. Elghazali, L. L. Gustafsson, M. I. Elbashir, and R. A. Mirghani. 2007. Pharmacokinetics of quinine and its metabolites in pregnant Sudanese women with uncomplicated Plasmodium falciparum malaria. J. Clin. Pharm. Ther. 32:15-19.
2. Adjei, G. O., J. A. Kurtzhals, O. P. Rodrigues, M. Alifrangis, L. C. Hoegberg, E. D. Kitcher, E. V. Badoe, R. Lamptey, and B. Q. Goka. 2008. Amodiaquineartesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year followup. Malar. J. 7:127.
3. Annerberg, A., T. Singtoroj, P. Tipmanee, N. J. White, N. P. Day, and N. Lindegardh. 2005. High throughput assay for the determination of lumefantrine in plasma. J. Chromatogr. B 822:330-333. (Pubitemid 40994071)
4. Ashley, E. A., K. Stepniewska, N. Lindegardh, A. Annerberg, A. Kham, A. Brockman, P. Singhasivanon, N. J. White, and F. Nosten. 2007. How much fat is necessary to optimize lumefantrine oral bioavailability? Trop. Med. Int. Health 12:195-200.
5. Ashley, E. A., K. Stepniewska, N. Lindegardh, R. McGready, A. Annerberg, R. Hutagalung, T. Singtoroj, G. Hla, A. Brockman, S. Proux, J. Wilahphaingern, P. Singhasivanon, N. J. White, and F. Nosten. 2007. Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria. Trop. Med. Int. Health 12:201-208.
6. Beal, S. L. 2001. Ways to fit a PK model with some data below the quantification limit. J. Pharmacokinet. Pharmacodyn. 28:481-504.
7. Beal, S. L., and L. B. Sheiner. 1982. Estimating population kinetics. Crit. Rev. Biomed. Eng. 8:195-222.
8. Beal., S. L., A. J. Boeckman., and L. B. Sheiner. 1992. NONMEM users guides. NONMEM Project Group, University of California at San Francisco.
9. Dellicour, S., S. Hall, D. Chandramohan, and B. Greenwood. 2007. The safety of artemisinins during pregnancy: a pressing question. Malar. J. 6:15. (Pubitemid 46321435)
10. Denis, M. B., R. Tsuyuoka, P. Lim, N. Lindegardh, P. Yi, S. N. Top., D. Socheat, T. Fandeur, A. Annerberg, E. M. Christophel, and P. Ringwald. 2006. Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop. Med. Int. Health 11:1800-1807.
11. Ezzet, F., R. Mull, and J. Karbwang. 1998. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. Br. J. Clin. Pharmacol. 46:553-561.
12. Ezzet, F., M. van Vugt, F. Nosten, S. Looareesuwan, and N. J. White. 2000. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob. Agents Chemother. 44:697-704.
13. Falade, C., M. Makanga, Z. Premji, C. E. Ortmann, M. Stockmeyer, and P. I. de Palacios. 2005. Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 99:459-467.
14. Green, M. D., A. M. van Eijk, F. O. van Ter Kuile, J. G. Ayisi, M. E. Parise, P. A. Kager, B. L. Nahlen, R. Steketee, and H. Nettey. 2007. Pharmacokinetics of sulfadoxine-pyrimethamine in HIV-infected and uninfected pregnant women in Western Kenya. J. Infect. Dis. 196:1403-1408.
15. Hatz, C., J. Soto, H. D. Nothdurft, T. Zoller, T. Weitzel, L. Loutan, F. Bricaire, F. Gay, G. D. Burchard, K. Andriano, G. Lefevre, P. I. De Palacios, and B. Genton. 2008. Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study. Am. J. Trop. Med. Hyg. 78:241-247.
16. Herrera, E., E. Amusquivar, I. Lopez-Soldado, and H. Ortega. 2006. Maternal lipid metabolism and placental lipid transfer. Horm. Res. 65(Suppl. 3):59-64.
17. Holford, N. 2005. The visual predictive check - superiority to standard diagnostic (Rorschach) plots, abstr. 738. 14th Meet. PAGE.
18. Hooker, A. C., C. E. Staatz, and M. O. Karlsson. 2007. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm. Res. 24:2187-2197.
19. Ilett, K. F., B. T. Ethell, J. L. Maggs, T. M. Davis, K. T. Batty, B. Burchell, T. Q. Binh, T. A. Thu le, N. C. Hung, M. Pirmohamed, B. K. Park, and G. Edwards. 2002. Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases. Drug Metab. Dispos. 30:1005-1012.
20. Jansen, F. H., E. Lesaffre, L. K. Penali, M. J. Zattera, H. Die-Kakou, and E. Bissagnene. 2007. Assessment of the relative advantage of various artesunate-based combination therapies by a multi-treatment Bayesian randomeffects meta-analysis. Am. J. Trop. Med. Hyg. 77:1005-1009.
21. Jonsson, E. N., and M. O. Karlsson. 1999. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58:51-64.
22. Kaivosaari, S., P. Toivonen, L. M. Hesse, M. Koskinen, M. H. Court, and M. Finel. 2007. Nicotine glucuronidation and the human UDP-glucuronosyl- transferase UGT2B10. Mol. Pharmacol. 72:761-768.
23. Karunajeewa, H. A., I. Mueller, M. Senn, E. Lin, I. Law, P. S. Gomorrai, O. Oa, S. Griffin, K. Kotab, P. Suano, N. Tarongka, A. Ura, D. Lautu, M. Page-Sharp, R. Wong, S. Salman, P. Siba, K. F. Ilett, and T. M. Davis. 2008. A trial of combination antimalarial therapies in children from Papua New Guinea. N. Engl. J. Med. 359:2545-2557.
24. Keuter, M., A. van Eijk, M. Hoogstrate, M. Raasveld, M. van de Ree, W. A. Ngwawe, W. M. Watkins, J. B. Were, and A. D. Brandling-Bennett. 1990. Comparison of chloroquine, pyrimethamine and sulfadoxine, and chlorproguanil and dapsone as treatment for falciparum malaria in pregnant and non-pregnant women, Kakamega District, Kenya. Br. Med. J. 301:466-470.
25. Lee, S. J., R. McGready, C. Fernandez, K. Stepniewska, M. K. Paw, S. J. Viladpai-Nguen, K. L. Thwai, L. Villegas, P. Singhasivanon, B. M. Greenwood, N. J. White, and F. Nosten. 2008. Chloroquine pharmacokinetics in pregnant and nonpregnant women with vivax malaria. Eur. J. Clin. Pharmacol. 64:987-992.
26. Lefevre, G., M. Bindschedler, F. Ezzet, N. Schaeffer, I. Meyer, and M. S. Thomsen. 2000. Pharmacokinetic interaction trial between co-artemether and mefloquine. Eur. J. Pharm. Sci. 10:141-151.
27. Lefevre, G., P. Carpenter, C. Souppart, H. Schmidli, M. McClean, and D. Stypinski. 2002. Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. Br. J. Clin. Pharmacol. 54:485-492.
28. Lefevre, G., and M. S. Thomsen. 1999. Clinical pharmacokinetics of artemether and lumefantrine (Riamet). Clin. Drug Investig. 18:467-480. (Pubitemid 30047534)
29. Mayxay, M., M. Khanthavong, N. Lindegardh, S. Keola, M. Barends, T. Pongvongsa, R. Yapom, A. Annerberg, S. Phompida, R. Phetsouvanh, N. J. White, and P. N. Newton. 2004. Randomized comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People's Democratic Republic. Clin. Infect. Dis. 39:1139-1147.
30. McGready, R., E. A. Ashley, E. Moo, T. Cho, M. Barends, R. Hutagalung, S. Looareesuwan, N. J. White, and F. Nosten. 2005. A randomized comparison of artesunate-atovaquone-proguanil versus quinine in treatment for uncomplicated falciparum malaria during pregnancy. J. Infect. Dis. 192:846-853.
31. McGready, R., K. Stepniewska, M. D. Edstein, T. Cho, G. Gilveray, S. Looareesuwan, N. J. White, and F. Nosten. 2003. The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. Eur. J. Clin. Pharmacol. 59:545-552.
32. McGready, R., K. Stepniewska, N. Lindegardh, E. A. Ashley, Y. La, P. Singhasivanon, N. J. White, and F. Nosten. 2006. The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. Eur. J. Clin. Pharmacol. 62:1021-1031.
33. McGready, R., K. Stepniewska, S. A. Ward, T. Cho, G. Gilveray, S. Looareesuwan, N. J. White, and F. Nosten. 2006. Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria. Eur. J. Clin. Pharmacol. 62:367-371.
34. McGready, R., S. O. Tan, E. Ashley, M. Pimanpanarak, S. J. Viladpai-Nguen, L. Phaiphun, K. Wustefeld, M. Barends, N. Laochan, L. Keereecharoen, N. Lindegardh, P. Singhasivanon, N. White, and F. Nosten. 2008. A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated Plasmodium falciparum treatment in pregnancy. PLoS Med. 5:1-17.
35. Mueller, E. A., M. van Vugt, W. Kirch, K. Andriano, P. Hunt, and P. I. de Palacios. 2006. Efficacy and safety of the six-dose regimen of artemetherlumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in adolescents and adults: a pooled analysis of individual patient data from randomized clinical trials. Acta Trop. 100:41-53. (Pubitemid 44830005)
36. Nakajima, M., T. Yamamoto, K. Nunoya, T. Yokoi, K. Nagashima, K. Inoue, Y. Funae, N. Shimada, T. Kamataki, and Y. Kuroiwa. 1996. Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes. J. Pharmacol. Exp. Ther. 277:1010-1015.
37. Nakajima, M., T. Yamamoto, K. Nunoya, T. Yokoi, K. Nagashima, K. Inoue, Y. Funae, N. Shimada, T. Kamataki, and Y. Kuroiwa. 1996. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab. Dispos. 24: 1212-1217.
38. Navaratnam, V., S. M. Mansor, N. W. Sit, J. Grace, Q. Li, and P. Olliaro. 2000. Pharmacokinetics of artemisinin-type compounds. Clin. Pharmacokinet. 39:255-270.
39. Noedl, H., Y. Se, K. Schaecher, B. L. Smith, D. Socheat, and M. M. Fukuda. 2008. Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med. 359:2619-2620.
40. Nosten, F., R. McGready, and T. Mutabingwa. 2007. Case management of malaria in pregnancy. Lancet Infect. Dis. 7:118-125.
41. Nosten, F., F. ter Kuile, L. Maelankirri, B. Decludt, and N. J. White. 1991. Malaria during pregnancy in an area of unstable endemicity. Trans. R. Soc. Trop. Med. Hyg. 85:424-429.
42. Price, R. N., A. C. Uhlemann, M. van Vugt, A. Brockman, R. Hutagalung, S. Nair, D. Nash, P. Singhasivanon, T. J. Anderson, S. Krishna, N. J. White, and F. Nosten. 2006. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin. Infect. Dis. 42:1570-1577.
43. Rahman, M. M., A. M. Dondorp, N. P. Day, N. Lindegardh, M. Imwong, M. A. Faiz, A. M. Bangali, A. T. Kamal, J. Karim, J. Kaewkungwal, and P. Singhasivanon. 2008. Adherence and efficacy of supervised versus non-supervised treatment with artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Bangladesh: a randomised controlled trial. Trans. R. Soc. Trop. Med. Hyg. 102:861-867.
44. Sagara, I., A. Diallo, M. Kone, M. Coulibaly, S. I. Diawara, O. Guindo, H. Maiga, M. B. Niambele, M. Sissoko, A. Dicko, A. Djimde, and O. K. Doumbo. 2008. A randomized trial of artesunate-mefloquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali. Am. J. Trop. Med. Hyg. 79:655-661.
45. Savic, R. M., D. M. Jonker, T. Kerbusch, and M. O. Karlsson. 2007. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J. Pharmacokinet. Pharmacodyn. 34:711-726.
46. Savic, R. M., J. J. Wilkins, and M. O. Karlsson. 2006. (Un)informativeness of empirical Bayes estimate-based diagnostics. AAPS J. 8:T3360. (Abstract.)
47. Stohrer, J. M., S. Dittrich, V. Thongpaseuth, V. Vanisaveth, R. Phetsouvanh, S. Phompida, F. Monti, E. M. Christophel, N. Lindegardh, A. Annerberg, and T. Jelinek. 2004. Therapeutic efficacy of artemether-lumefantrine and artesunate-mefloquine for treatment of uncomplicated Plasmodium falciparum malaria in Luang Namtha Province, Lao People's Democratic Republic. Trop. Med. Int. Health 9:1175-1183.
48. van Agtmael, M. A., C. A. Van Der Graaf, T. K. Dien, R. P. Koopmans, and C. J. van Boxtel. 1998. The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects. Eur. J. Drug Metab. Pharmacokinet. 23:429-436.
49. van Vugt, M., F. Ezzet, L. Phaipun, F. Nosten, and N. J. White. 1998. The relationship between capillary and venous concentrations of the antimalarial drug lumefantrine (benflumetol). Trans. R. Soc. Trop. Med. Hyg. 92:564-565.
50. Wahlby, U., M. R. Bouw, E. N. Jonsson, and M. O. Karlsson. 2002. Assessment of type I error rates for the statistical sub-model in NONMEM. J. Pharmacokinet. Pharmacodyn. 29:251-269.
51. Wahlby, U., E. N. Jonsson, and M. O. Karlsson. 2001. Assessment of actual significance levels for covariate effects in NONMEM. J. Pharmacokinet. Pharmacodyn. 28:231-252.
52. Wernsdorfer, W. H. 1994. Epidemiology of drug resistance in malaria. Acta Trop. 56:143-156.
53. White, N. J., R. M. McGready, and F. H. Nosten. 2008. New medicines for tropical diseases in pregnancy: catch-22. PLoS Med. 5:e133.
54. White, N. J., K. Stepniewska, K. Barnes, R. N. Price, and J. Simpson. 2008. Simplified antimalarial therapeutic monitoring: using the day-7 drug level? Trends Parasitol. 24:159-163.
55. White, N. J., M. van Vugt, and F. Ezzet. 1999. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. Clin. Pharmacokinet. 37:105-125.
56. WHO. 2003. Assessment of the safety of artemisinins in pregnancy. WHO, Geneva, Switzerland.
57. WHO. 2006. Guidelines for the treatment of malaria. WHO, Geneva, Switzerland.
58. Wilkins, J. J. 2005. NONMEMory: a run management tool for NONMEM. Comput. Methods Programs Biomed. 78:259-267.
59. Zongo, I., G. Dorsey, N. Rouamba, H. Tinto, C. Dokomajilar, R. T. Guiguemde, P. J. Rosenthal, and J. B. Ouedraogo. 2007. Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. Lancet 369:491-498. (Pubitemid 46223467)